BRIEF REPORT

REVISED Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? [version 4; peer review: 2 approved, 1 approved with reservations]

Dirk W. Lachenmeier , Stephanie Habel, Berit Fischer, Frauke Herbi, Yvonne Zerbe, Verena Bock, Tabata Rajcic de Rezende, Stephan G. Walch , Constanze Sproll

Chemisches und Veterinäruntersuchungsamt (CVUA) Karlsruhe, Karlsruhe, 76187, Germany

V4 First published: 08 Aug 2019, 8:1394
<https://doi.org/10.12688/f1000research.19931.1>
 Second version: 11 Feb 2020, 8:1394
<https://doi.org/10.12688/f1000research.19931.2>
 Third version: 19 Aug 2020, 8:1394
<https://doi.org/10.12688/f1000research.19931.3>
 Fourth version: 30 Jul 2021, 8:1394
<https://doi.org/10.12688/f1000research.19931.4>
 Latest published: 10 Nov 2022, 8:1394
<https://doi.org/10.12688/f1000research.19931.5>

Abstract

Cannabidiol (CBD)-containing products are widely marketed as over the counter products, mostly as food supplements. Adverse effects reported in anecdotal consumer reports or during clinical studies were first assumed to be due to hydrolytic conversion of CBD to psychotropic Δ^9 -tetrahydrocannabinol (Δ^9 -THC) in the stomach after oral consumption. However, research of pure CBD solutions stored in simulated gastric juice or subjected to various storage conditions such as heat and light with specific liquid chromatographic/tandem mass spectrometric (LC/MS/MS) and ultra-high pressure liquid chromatographic/quadrupole time-of-flight mass spectrometric (UPLC-QTOF) analyses was unable to confirm THC formation. Another hypothesis for the adverse effects of CBD products may be residual Δ^9 -THC concentrations in the products as contamination, because most of them are based on hemp extracts containing the full spectrum of cannabinoids besides CBD. Analyses of 181 food products of the German market (mostly CBD oils) confirmed this hypothesis: 21 products (12%) contained Δ^9 -THC above the lowest observed adverse effect level (2.5 mg/day). Inversely, CBD was present in the products below the no observed adverse effect level. Hence, it may be assumed that the adverse effects of some commercial CBD products are based on a low-dose effect of Δ^9 -THC and not due to effects of CBD itself. The

Open Peer Review

Approval Status

	1	2	3
version 5 (revision) 10 Nov 2022			
version 4 (revision) 30 Jul 2021			
version 3 (revision) 19 Aug 2020			
version 2 (revision) 11 Feb 2020			
version 1 08 Aug 2019			

1. **Arno Hazekamp** , Hazekamp Herbal Consulting BV, Leiden, The Netherlands
2. **Linda A. Parker**, University of Guelph, Guelph, Canada

safety, efficacy and purity of commercial CBD products is highly questionable, and all of the products in our sample collection showed various non-conformities to European food law such as unsafe Δ^9 -THC levels, hemp extracts or CBD isolates as non-approved novel food ingredients, non-approved health claims, and deficits in mandatory food labelling requirements. In view of the growing market for such lifestyle products, the effectiveness of the instrument of food business operators' own responsibility for product safety and regulatory compliance must obviously be challenged, and a strong regulatory framework for hemp products needs to be devised.

Keywords

Tetrahydrocannabinol, cannabidiol, Cannabis sativa, hemp, food supplements, risk assessment, drug effects

3. **Volker Auwärter** , Medical Center -

University of Freiburg, Freiburg, Germany

Any reports and responses or comments on the article can be found at the end of the article.

This article is included in the **Agriculture, Food and Nutrition** gateway.

Corresponding author: Dirk W. Lachenmeier (lachenmeier@web.de)

Author roles: **Lachenmeier DW:** Conceptualization, Formal Analysis, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Habel S:** Data Curation, Writing – Review & Editing; **Fischer B:** Investigation, Writing – Review & Editing; **Herbi F:** Investigation, Writing – Review & Editing; **Zerbe Y:** Investigation, Writing – Review & Editing; **Bock V:** Formal Analysis, Writing – Review & Editing; **Rajcic de Rezende T:** Formal Analysis, Writing – Review & Editing; **Walch SG:** Resources, Supervision, Writing – Review & Editing; **Sproll C:** Conceptualization, Formal Analysis, Investigation, Methodology, Supervision, Validation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2021 Lachenmeier DW *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Lachenmeier DW, Habel S, Fischer B *et al.* **Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?** [version 4; peer review: 2 approved, 1 approved with reservations] F1000Research 2021, 8:1394 <https://doi.org/10.12688/f1000research.19931.4>

First published: 08 Aug 2019, 8:1394 <https://doi.org/10.12688/f1000research.19931.1>

REVISED Amendments from Version 3

The text was clarified considering the two reviews of our commentary in F1000Research 2020, 9:900. Some further references on adverse effects of cannabidiol as well as on stability studies were included. The criticism regarding sample size of the original peer review was further addressed by including analytical results of 114 additional samples analyzed during 2020 into Table 2 (resulting in n=181). The toxicological assessment is now exclusively based on EFSA's acute reference dose.

Any further responses from the reviewers can be found at the end of the article

Introduction

Since hemp has been re-approved for cultivation as an industrial crop in the form of low Δ^9 -tetrahydrocannabinol (Δ^9 -THC) hemp (*Cannabis sativa* L.) varieties in the European Union (EU), components of the hemp plant are increasingly used for the production of foods and other consumer products such as liquids for electronic cigarettes¹.

From all hemp constituents, cannabidiol (CBD) is currently the compound with highest interest. In contrast to Δ^9 -THC, the major narcotic constituent of hemp, CBD is a non-psychoactive cannabinoid. It is currently being tested for its possible antispasmodic, anti-inflammatory, anxiolytic and antiemetic effects as a drug, e.g. for the treatment of epilepsy^{2,3}. However, CBD products of all kinds can now also be purchased in organic shops, drug stores, specialised hemp and CBD stores, but also in supermarkets and via the Internet, often by advertising questionable “cure-all” properties including various unspecific health advantages. The marketing of CBD products is based on the current “hype” around medicinal hemp products, whereby the CBD products are offered as a supposedly safe alternative, promised as being free of psychoactive components or their adverse effects⁴. With the exception of the treatment of Dravet's syndrome, there is little clinical data on the efficacy and safety of CBD^{5,6}. Cannabidiol is currently approved in the EU in a single medicinal product, namely Epidiolex® for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy. Apart from that, extemporaneous preparations in pharmacies are legally available on prescription in Germany and some other countries. However, most of the CBD products worldwide are available as food supplements or CBD-containing hemp extracts are used as ingredient in other foods.

Commercial CBD products are usually crude extracts from whole hemp plants (i.e., including flowers and stems). In other ways (e.g., in extracting the food-approved plant parts such as seeds), contents in the range of 1–10% CBD, which are typically advertised, cannot be achieved. Also, the limited available literature and manufacturer data confirm that CBD products are usually extracted by supercritical CO₂ or with solvents such as ethanol or isopropanol from the entire hemp plant material, which typically has been decarboxylated before

the process^{6,7}. No further specific enrichment or purification of CBD is often conducted, so that the commercial extracts are regularly a cannabinoid mixture rather than pure CBD. Otherwise, extracts may be cleaned with different processes such as winterization, or partial fractionation using supercritical CO₂. These extracts, which are typically called “full spectrum extracts” in difference to chemically pure CBD (such as isolated or synthesized CBD), are then mixed into ordinary edible oils such as sunflower oil, olive oil or hemp seed oil to obtain the so-called CBD oil⁶.

The strategy to market CBD products as food supplements within the framework of food regulations seems to be the most common approach of CBD sellers. The most prevalent food supplement products are CBD oils in liquid form or hemp extract containing capsules. Some other products, derived from hemp extracts, are CBD chewing gum, and cannabis resin, wax or pollen products, while so-called “CBD flowers” are typically sold as plant material to prepare a tea-like infusion or as an herbal product for smoking.

However, no significant food consumption of CBD products has been documented before 15 May 1997. These products are therefore classified as “novel” in the Novel Food catalogue of the European Commission under the entry “cannabinoids” and therefore require approval according to the Novel Food Regulation. Up to date (as of July 2021), no approved application is documented while the approval process of five applications for synthetic CBD is currently in progress. Basically, all available CBD products based on hemp extract but also those based on isolated or synthesized CBD, which are marketed as food or food supplement within the EU, are therefore illegally sold². To circumvent the strict safety requirements for medicinal or food products, some CBD products may be sold as other product categories (e.g., cosmetics, veterinary supplements, waxes, flavourings, air fresheners or room fragrances), but the off-label use, human consumption, is clearly intended.

Despite the enforcement efforts of the food and medicinal product control authorities (e.g. the EU's rapid alert system for food and feed (RASFF) lists over 160 alerts for CBD since 2018), a multitude of CBD products is available on the internet and in some retail stores, so that CBD is currently easily available to consumers.

Despite the lack of mandatory nutriviigilance in the EU, anecdotal cases ranging from indisposition to Δ^9 -THC-like effects have been reported to our institute from food control authorities in the German Federal State of Baden-Württemberg in the context of consumer complaint cases regarding CBD products. Several case reports of adverse effects of CBD products have also been published^{8–11}, and a survey of 135 CBD users in the USA detected a high prevalence of adverse effects (30% dry mouth, 22% feeling high, 20% change in appetite, 19% fatigue)¹². Additionally, some paediatric studies in epilepsy patients with orally administered CBD also reported adverse effects such as drowsiness and fatigue that could be

explained by pharmacological properties of Δ^9 -THC rather than of CBD^{13–15}. Respiratory depression was reported in a case of CBD overdose in a paediatric patient¹⁶.

Diarrhoea was an adverse outcome associated with CBD treatment in a meta-analysis of randomized clinical trials, after excluding studies of childhood epilepsy¹⁷. Post marketing safety surveillance of a full spectrum hemp extract reported gastrointestinal symptoms as most common adverse effect, however, they were infrequent (0.03%)¹⁸. More recently, the epidemiology of CBD-related cases in the national poison data system of the USA was assessed. Cannabidiol cases increased from 0% in 2009–2018 to 17% of all cases in 2019¹⁹. Among the exposures in which CBD was the only reported substance (n=1275), the most common symptoms were mild central nervous system depression (10%), tachycardia (6%), dizziness/vertigo (5%), vomiting (5%), nausea (5%) and agitation (4%)²⁰.

Currently there are three hypotheses for the cause of the adverse effects: (i) a direct pharmacological effect of CBD, (ii) the degradation of CBD to Δ^9 -THC due to acidic hydrolysis in the stomach following oral consumption, and (iii) Δ^9 -THC directly contained in the products as by-product due to co-extraction and enrichment or contamination such as formation from CBD degradation during storage. In this article, the hypotheses are investigated including new evidence from original data.

Methods

CBD degradation

To investigate CBD degradation into Δ^9 -THC under acidic conditions, differently concentrated CBD in methanolic solutions was used in a range corresponding to typical amounts consumed with supplements based on commercial CBD (Supelco Cerilliant, certified reference material, #C-045, 1.0 mg/mL in methanol) supplied by Merck (Darmstadt, Germany). These solutions were exposed to an artificial gastric juice as well as different incubation times and stress factors such as storage under light and heat (see [Table 1](#) for full experimental design). The solutions were stored either in standard freezer (−18°C) or refrigerator (8°C) or at room temperature (20°C). Increased temperatures were achieved using a thermostatically controlled laboratory drying oven type “UT6120” (Heraeus, Langensfeld, Germany) set to either 37°C or 60°C. The daylight condition was achieved by storage at a window (south side). For ultraviolet light exposure, six 25 W ultraviolet (UV) fluorescent tubes type “excellent E” (99.1% UVA) built into a facial tanner type “NT 446 U” (Dr. Kern GmbH, Mademühlen, Germany) were placed 15 cm from the surface of the solutions (open sample vials). In deviation of an experimental protocol of Merrick *et al.*²¹, a gastric juice without addition of surfactants was used, which was strictly produced according to the European pharmacopoeia²² (0.020 g NaCl + 0.032 g pepsin + 0.8 mL HCl (1 mol/L), filled up to 10 mL with water). As pure CBD was available only in methanolic solution, the final experimental setups contained 0.08 mol/L HCl and 1%

methanol due to dilution (methanol residues in this order of magnitude are not interfering with the analysis).

To ensure the utmost analytical validity, all samples were independently measured on two different instruments, using a triple quadrupole mass spectrometer (TSQ Vantage, Thermo Fisher Scientific, San Jose, CA, USA) coupled with an LC system (1100 series, Agilent, Waldbronn, Germany) and also using a quadrupole time-of-flight (QTOF) mass spectrometer (X500, Sciex, Darmstadt, Germany) coupled with an UPLC system (1290 series, Agilent, Waldbronn, Germany). Both systems used the same type of separation column (Luna Omega Polar C18, 150 × 2.1 mm, 1.6 µm, 100 Å, Phenomenex, Aschaffenburg, Germany). The separation was isocratic with 25 % water (0.1 % formic acid) and 75 % acetonitrile (0.1 % formic acid) and a flow of 0.3 mL/min. In case of QTOF with 35 % water (0.1 % formic acid) and 65 % acetonitrile (0.1 % formic acid) and a flow of 0.45 mL/min. The evaluation took place after fragmentation of the mother ion into three mass traces for each compound. As quantifier for Δ^9 -THC and CBD, the mass transition m/z 315 to 193 was used. In case of QTOF, quantification was conducted over accurate mass and control of fragmentation pattern. CBD eluted as one of the first cannabinoids, a few minutes before Δ^9 -THC. As internal standards Δ^9 -THC-d₃ (Supelco Cerilliant #T-011, 1.0 mg/mL in methanol) was used for the quantification of Δ^9 -THC (Supelco Cerilliant #T-005, 1.0 mg/mL in methanol), and cannabidiol-d₃ (Supelco Cerilliant #C-084, 100 µg/mL in methanol) for quantification of CBD (Supelco Cerilliant #C-045, 1.0 mg/mL in methanol). The certified reference materials were obtained as solutions in ampoules of 1 mL, all supplied by Merck (Darmstadt, Germany). A limit of detection (LOD) of 5 ng/mL was determined. For both procedures, relative standard deviations better than 5% were achieved. Both methods are able to chromatographically separate Δ^9 -THC and CBD from their acids. Specificity was ensured using a certified reference material as a reference standard of THCA (Supelco Cerilliant #T-093, 1.0 mg/mL in acetonitrile). Baseline separation was achieved between Δ^9 -THC, Δ^8 -THC and THCA. Therefore, the reported values in this study are specific for Δ^9 -THC and CBD. In contrast to some previous studies based on gas chromatography, we do not report “total THC” or “total CBD”, which would be a sum of the free form and its acid.

Δ^9 -THC contamination of commercial products

To study the possible influence of natively contained Δ^9 -THC in hemp products as a cause for adverse effects, a sampling of available CBD products registered as food supplement in the German State Baden-Württemberg, other available hemp extract products in retail, as well as all products available at the warehouse of a large internet retailer were sampled between December 2018 and December 2020. A total of 181 samples (see [Table 2](#) for product designations) were analysed using the above-described liquid chromatographic method with tandem mass spectrometric detection (LC-MS/MS) for Δ^9 -THC content. For 2020 samples, the following parameters of the method were changed: separation column (Raptor,

Table 1. Cannabidiol (CBD) stability experiments under various storage conditions.

Experiment	Temperature (°C)	Light exposure	Storage time	Storage medium	CBD concentration in medium (µg/L)	Δ ⁹ -THC formation ¹
Negative control	-18	None	14 days	Methanol	1000	0%
Light	20	None	3 days	Methanol	1000	0%
	20	None	14 days	Methanol	1000	0%
	20	Daylight	3 days	Methanol	1000	0%
	20	Daylight	14 days	Methanol	1000	0%
	20	UVA	1 h	Methanol	1000	0%
	20	UVA	3 h	Methanol	1000	0%
	20	UVA	3 h	Methanol	1000	0%
Temperature	20	None	5 days	Methanol	1000	0%
	20	None	14 days	Methanol	1000	0%
	8	None	5 days	Methanol	1000	0%
	8	None	14 days	Methanol	1000	0%
	37	None	3 h	Methanol	1000	0%
	60	None	1 h	Methanol	1000	0%
Simulated gastric juice	37	None	1 h	Simulated gastric juice	200	0%
	37	None	2 h	Simulated gastric juice	200	0%
	37	None	3 h	Simulated gastric juice	200	0%
	37	None	1 h	Simulated gastric juice	400	0%
	37	None	2 h	Simulated gastric juice	400	0%
	37	None	3 h	Simulated gastric juice	400	0%
Positive control	20	None	14 days	Methanol / 1 mol/L HCl (50:50)	500	27%

¹ Average of LC-MS/MS and UPLC-QTOF measurements (n=2) (for raw results see dataset²³, table sheet 1). Δ⁹-THC formation calculated as % in relation to original CBD content.

Abbreviations: CBD: cannabidiol; Δ⁹-THC: Δ⁹-tetrahydrocannabinol; UVA: ultraviolet A; LC-MS/MS: liquid chromatography/tandem mass spectrometry; UPLC-QTOF: ultra-high pressure liquid chromatography/quadrupole time-of-flight mass spectrometry

Table 2. Results of THC analysis in commercial hemp-based products from the German market (2018–2020).

Sample ID	Product	CBD [mg/day] (recommended daily dose according to labelling)	CBD [mg/day] (analysis) ¹	Δ ⁹ -THC [mg/day] (analysis) ¹	Toxicity assessment according to Ref. 2
190267605	CBD oil	2000 ²	3140	30	THC > LOAEL
200517333	Hemp CBD Oil	1500	- ³	15	THC > LOAEL
180630663	CBD oil supplement	200	- ³	9.1	THC > LOAEL
200536492	CBD oil	2400	- ³	6.7	THC > LOAEL
200055880	CBD liquid - ⁴	400	272	6.5	THC > LOAEL
200427032	Hemp seed oil	- ⁵	- ³	6.4	THC > LOAEL
190595270	Hemp tea with flowers	- ⁵	- ³	5.1	THC > LOAEL
190490183	Hemp tea with flowers	- ⁵	19	4.0	THC > LOAEL
180776480	CBD oil supplement	74	51	3.9	THC > LOAEL
190595273	Hemp tea with flowers	- ⁵	- ³	3.6	THC > LOAEL

Sample ID	Product	CBD [mg/day] (recommended daily dose according to labelling)	CBD [mg/day] (analysis) ¹	Δ ⁹ -THC [mg/day] (analysis) ¹	Toxicity assessment according to Ref. ²
190595267	Hemp tea with flowers	- ⁵	16	3.3	THC > LOAEL
190203194	CBD pollen	- ⁵	- ³	2.6	THC > LOAEL
190495001	Hemp tea with flowers	(3.8 % CBD/package)	- ³	(2.3) ⁶	THC > LOAEL
180598182	CBD hemp flower supplement	500	- ³	(2.3) ⁶	THC > LOAEL
190203193	CBD wax	660	860	(1.7) ⁶	THC > LOAEL
180781746	CBD chewing gum	15	30	(1.5) ⁶	THC > LOAEL
190400870	Hemp tea with flowers	"high CBD content"	16	(1.4) ⁶	THC > LOAEL
180198245	CBD buds (hemp flowers & leaves)	- ⁵	- ³	(1.3) ⁶	THC > LOAEL
180598187	CBD hemp flower supplement	250	- ³	(1.3) ⁶	THC > LOAEL
180198246	CBD buds (hemp flowers & leaves)	- ⁵	- ³	(1.3) ⁶	THC > LOAEL
190176314	Hemp tea with leaves and flowers	50	9	(0.5) ⁶	THC > LOAEL
200308438	Hemp tea with flowers	- ⁵	- ³	2.4	ARfD < THC < LOAEL
200498262	Hemp tea	- ⁵	- ³	2.3	ARfD < THC < LOAEL
200404608	CBD liquid - ⁴	500	- ³	1.7	ARfD < THC < LOAEL
190141197	CBD oil supplement	22.32	- ³	1.6	ARfD < THC < LOAEL
190722404	Hemp tea	- ⁵	3.8	1.3	ARfD < THC < LOAEL
200055883	CBD liquid- ⁴	300	256	1.2	ARfD < THC < LOAEL
200049885	CBD liquid- ⁴	300	229	1.0	ARfD < THC < LOAEL
200064492	CBD liquid- ⁴	100	73	0.9	ARfD < THC < LOAEL
200308470	CBD liquid- ⁴	- ⁵	- ³	0.8	ARfD < THC < LOAEL
200100780	Hemp tea with flowers	- ⁵	- ³	0.7	ARfD < THC < LOAEL
190203191	Supplement with hemp extract	- ⁵	- ³	0.7	ARfD < THC < LOAEL
200461203	CBD liquid- ⁴	- ⁵	- ³	0.7	ARfD < THC < LOAEL
200663956	CBD flowers	- ⁵	- ³	0.7	ARfD < THC < LOAEL
200308466	CBD liquid- ⁴	- ⁵	- ³	0.7	ARfD < THC < LOAEL
200663959	CBD flowers	- ⁵	- ³	0.7	ARfD < THC < LOAEL
190698985	CBD oil supplement	40	- ³	0.6	ARfD < THC < LOAEL
200663960	CBD flowers	- ⁵	- ³	0.6	ARfD < THC < LOAEL
190400871	Hemp tea with flowers	- ⁵	8	0.6	ARfD < THC < LOAEL
200663957	CBD flowers	- ⁵	- ³	0.6	ARfD < THC < LOAEL
200622669	Hemp tea with leaves	- ⁵	- ³	0.6	ARfD < THC < LOAEL
190199739	Supplement with hemp extract	- ⁵	34	0.5	ARfD < THC < LOAEL
190660814	CBD oil supplement	30	- ³	0.5	ARfD < THC < LOAEL
200064491	CBD liquid- ⁴	100	58	0.5	ARfD < THC < LOAEL
200100857	Hemp tea with flowers	- ⁵	5	0.5	ARfD < THC < LOAEL
200713361	CBD oil	31	- ³	0.5	ARfD < THC < LOAEL
200461204	CBD liquid- ⁴	- ⁵	- ³	0.5	ARfD < THC < LOAEL

Sample ID	Product	CBD [mg/day] (recommended daily dose according to labelling)	CBD [mg/day] (analysis) ¹	Δ ⁹ -THC [mg/day] (analysis) ¹	Toxicity assessment according to Ref. 2
200663958	CBD flowers	-. ⁵	-. ³	0.4	ARfD < THC < LOAEL
190810601	CBD liquid- ⁴	250	214	0.4	ARfD < THC < LOAEL
190207787	CBD oil supplement	67.5	95	0.4	ARfD < THC < LOAEL
190332551	CBD oil supplement	42	-. ³	0.3	ARfD < THC < LOAEL
190332552	CBD oil supplement	84	-. ³	0.3	ARfD < THC < LOAEL
200498263	Hemp tea	-. ⁵	-. ³	0.3	ARfD < THC < LOAEL
200669073	CBD oil	-. ⁵	-. ³	0.3	ARfD < THC < LOAEL
200663954	CBD flowers	-. ⁵	-. ³	0.3	ARfD < THC < LOAEL
200308440	CBD oil	-. ⁵	-. ³	0.3	ARfD < THC < LOAEL
190332553	CBD oil supplement	166	-. ³	0.3	ARfD < THC < LOAEL
190540832	Supplement with hemp extract	-. ⁵	-. ³	0.3	ARfD < THC < LOAEL
200404603	CBD liquid- ⁴	1000	-. ³	0.2	ARfD < THC < LOAEL
180565755	CBD oil supplement	24	18	0.2	ARfD < THC < LOAEL
190480260	Supplement with hemp juice powder	-. ⁵	-. ³	0.2	ARfD < THC < LOAEL
190203189	Supplement with hemp extract	-. ⁵	-. ³	0.2	ARfD < THC < LOAEL
190180559	CBD wax	700	-. ³	0.2	ARfD < THC < LOAEL
190661483	CBD oil supplement	24	0.1	0.2	ARfD < THC < LOAEL
200308465	CBD liquid- ⁴	-. ⁵	-. ³	0.2	ARfD < THC < LOAEL
200586742	Herbal Tea	-. ⁵	-. ³	0.2	ARfD < THC < LOAEL
180565756	CBD oil supplement	12	9	0.2	ARfD < THC < LOAEL
190480266	Hemp tea with leaves	-. ⁵	-. ³	0.2	ARfD < THC < LOAEL
200308444	CBD oil	-. ⁵	-. ³	0.2	ARfD < THC < LOAEL
200308441	CBD oil	-. ⁵	-. ³	0.2	ARfD < THC < LOAEL
200663955	CBD flowers	-. ⁵	-. ³	0.2	ARfD < THC < LOAEL
190394018	CBD oil supplement	2000	-. ³	0.2	ARfD < THC < LOAEL
190351382	CBD oil supplement	24	-. ³	0.2	ARfD < THC < LOAEL
190480263	Supplement with hemp extract	-. ⁵	-. ³	0.2	ARfD < THC < LOAEL
190595265	Syrup with hemp flower extract	-. ⁵	-. ³	0.2	ARfD < THC < LOAEL
200064256	CBD liquid- ⁴	333	294	0.2	ARfD < THC < LOAEL
200308447	CBD oil	-. ⁵	-. ³	0.2	ARfD < THC < LOAEL
190080917	Supplement with hemp extract	-. ⁵	4	0.1	ARfD < THC < LOAEL
200308442	CBD oil	-. ⁵	-. ³	0.1	ARfD < THC < LOAEL
200669072	CBD oil	-. ⁵	-. ³	0.1	ARfD < THC < LOAEL
210094426	CBD oil	-. ⁵	-. ³	0.1	ARfD < THC < LOAEL
200055882	CBD liquid- ⁴	100	45	0.1	ARfD < THC < LOAEL
200557132	Hemp tea	-. ⁵	-. ³	0.1	ARfD < THC < LOAEL
200068141	CBD liquid- ⁴	500	400	0.1	ARfD < THC < LOAEL

Sample ID	Product	CBD [mg/day] (recommended daily dose according to labelling)	CBD [mg/day] (analysis) ¹	Δ ⁹ -THC [mg/day] (analysis) ¹	Toxicity assessment according to Ref. 2
200308445	CBD oil	-. ⁵	-. ³	0.1	ARfD < THC < LOAEL
200055874	CBD liquid- ⁴	600	578	0.1	ARfD < THC < LOAEL
200541751	Tea with hemp leaves	-. ⁵	-. ³	0.1	ARfD < THC < LOAEL
190303096	CBD chewing gum	5	-. ³	0.1	ARfD < THC < LOAEL
190696142	CBD oil	24	0.02	0.1	ARfD < THC < LOAEL
200498257	CBD oil	50	-. ³	0.1	ARfD < THC < LOAEL
190696141	CBD oil supplement	7	-. ³	0.1	ARfD < THC < LOAEL
200421839	CBD oil	8.8	-. ³	0.1	ARfD < THC < LOAEL
200424875	CBD oil	8.8	-. ³	0.1	ARfD < THC < LOAEL
190304229	CBD chewing gum	5	-. ³	0.1	ARfD < THC < LOAEL
200498265	Hemp tea	-. ⁵	-. ³	0.1	ARfD < THC < LOAEL
200421841	CBD hemp extract supplement	16	-. ³	0.1	ARfD < THC < LOAEL
200429640	CBD hemp extract supplement	16	-. ³	0.1	ARfD < THC < LOAEL
200434661	CBD hemp extract supplement	16	-. ³	0.1	ARfD < THC < LOAEL
200442385	CBD hemp extract supplement	16	-. ³	0.1	ARfD < THC < LOAEL
190661482	CBD oil	24	0.09	0.1	ARfD < THC < LOAEL
190689579	CBD oil supplement	24	-. ³	0.1	ARfD < THC < LOAEL
200406179	CBD oil	600	-. ³	0.1	ARfD < THC < LOAEL
190080916	Supplement with hemp extract	-. ⁵	-. ³	0.1	ARfD < THC < LOAEL
200100859	CBD oil	47.5	-. ³	0.09	THC < ARfD
200308450	CBD oil	-. ⁵	-. ³	0.09	THC < ARfD
200308443	CBD oil	-. ⁵	-. ³	0.09	THC < ARfD
200421840	CBD flavour oil	-. ⁵	-. ³	0.09	THC < ARfD
200049887	CBD liquid- ⁴	100	67	0.09	THC < ARfD
190480151	Supplement with hemp juice powder	-. ⁵	-. ³	0.08	THC < ARfD
200633636	CBD oil	11	-. ³	0.08	THC < ARfD
200625847	CBD oil	24	-. ³	0.08	THC < ARfD
200625849	CBD oil	18	-. ³	0.08	THC < ARfD
200421842	CBD oil	12	-. ³	0.08	THC < ARfD
200429639	CBD oil	12	-. ³	0.08	THC < ARfD
200100781	Hemp extract	-. ⁵	-. ³	0.08	THC < ARfD
200633637	CBD oil	20	-. ³	0.08	THC < ARfD
200699058	Hemp CBD supplement	30	-. ³	0.07	THC < ARfD
190578889	Hemp seed with leaves (tea)	-. ⁵	-. ³	0.07	THC < ARfD
190639434	CBD oil supplement	50	-. ³	0.07	THC < ARfD
200308449	CBD oil	-. ⁵	-. ³	0.07	THC < ARfD
190639431	CBD oil supplement	38	-. ³	0.07	THC < ARfD

Sample ID	Product	CBD [mg/day] (recommended daily dose according to labelling)	CBD [mg/day] (analysis) ¹	Δ^9 -THC [mg/day] (analysis) ¹	Toxicity assessment according to Ref. ²
200405892	Hemp tea	-. ⁵	-. ³	0.07	THC < ARfD
190203192	Supplement with hemp extract	-. ⁵	-. ³	0.07	THC < ARfD
200633635	CBD oil	9	-. ³	0.07	THC < ARfD
200040660	CBD liquid- ⁴	30	25	0.06	THC < ARfD
200308446	CBD oil	-. ⁵	-. ³	0.06	THC < ARfD
200308448	CBD oil	-. ⁵	-. ³	0.06	THC < ARfD
200092586	Hemp tea	-. ⁵	-. ³	0.06	THC < ARfD
200055034	CBD liquid- ⁴	120	95	0.06	THC < ARfD
200404607	CBD liquid- ⁴	1000	-. ³	0.06	THC < ARfD
200622690	Supplements with hemp	-. ⁵	-. ³	0.05	THC < ARfD
190304228	CBD supplement	20	-. ³	0.05	THC < ARfD
190468594	CBD oil supplement	4	-. ³	0.05	THC < ARfD
190626611	Supplement with hemp juice powder	-. ⁵	-. ³	0.05	THC < ARfD
200530868	CBD oil	-. ⁵	-. ³	0.04	THC < ARfD
190626620	Supplement with hemp juice powder	-. ⁵	-. ³	0.04	THC < ARfD
200626107	CBD oil	1.5	-. ³	0.04	THC < ARfD
200626105	CBD oil	2.4	-. ³	0.04	THC < ARfD
200068143	CBD liquid- ⁴	100	62	0.04	THC < ARfD
200429638	CBD flavour oil	15.5	-. ³	0.03	THC < ARfD
200530872	CBD oil	-. ⁵	-. ³	0.03	THC < ARfD
200666376	CBD oil	50	-. ³	0.03	THC < ARfD
200068142	CBD liquid- ⁴	100	57	0.03	THC < ARfD
190629508	CBD oil supplement	18	-. ³	0.03	THC < ARfD
200699054	CBD oil	12.6	-. ³	0.03	THC < ARfD
200578707	CBD oil	6.5	-. ³	0.03	THC < ARfD
200055873	CBD liquid- ⁴	500	50	0.02	THC < ARfD
200699051	CBD oil	50	-. ³	0.02	THC < ARfD
200582816	Hemp Oil	-. ⁵	-. ³	0.02	THC < ARfD
190629507	Supplement with hemp extract	12	-. ³	0.02	THC < ARfD
200530867	CBD oil	-. ⁵	-. ³	0.02	THC < ARfD
200100856	CBD oil	-. ⁵	-. ³	0.02	THC < ARfD
200055032	CBD liquid- ⁴	30	20	0.02	THC < ARfD
200626089	CBD oil	29	-. ³	0.02	THC < ARfD
200530865	CBD oil	-. ⁵	-. ³	0.02	THC < ARfD
200622701	Supplements with hemp	18	-. ³	0.02	THC < ARfD
190348163	Supplement with hemp extract	2	-. ³	0.02	THC < ARfD
200626099	CBD oil	15	-. ³	0.02	THC < ARfD

Sample ID	Product	CBD [mg/day] (recommended daily dose according to labelling)	CBD [mg/day] (analysis) ¹	Δ ⁹ -THC [mg/day] (analysis) ¹	Toxicity assessment according to Ref. 2
200049883	CBD liquid ⁻⁴	100	55	0.01	THC < ARfD
190601859	Supplement with hemp extract	100	- ³	0.01	THC < ARfD
190272024	CBD oil	27	38	0.01	THC < ARfD
190387558	CBD supplement	10	- ³	0.01	THC < ARfD
190810624	CBD liquid ⁻⁴	100	61	0.009	THC < ARfD
200117019	Hemp juice shot	- ⁵	0.2	0.008	THC < ARfD
190664273	Cannabis shot (one portion)	- ⁵	- ³	0.008	THC < ARfD
200055056	CBD liquid ⁻⁴	30	17	0.008	THC < ARfD
200626101	CBD oil	7.5	- ³	0.008	THC < ARfD
200064257	CBD liquid ⁻⁴	30	13	0.007	THC < ARfD
200626102	CBD oil	8.5	- ³	0.006	THC < ARfD
200626097	CBD oil	30	- ³	0.006	THC < ARfD
190387560	CBD supplement	5	- ³	0.006	THC < ARfD
200626094	CBD oil	38	- ³	0.005	THC < ARfD
190378411	CBD Hemp Bears	20	- ³	0.004	THC < ARfD
200622667	Supplements with hemp	- ⁵	0.09	0.004	THC < ARfD
190672010	CBD oil supplement	14	- ³	0.002	THC < ARfD
190387553	CBD supplement	5	- ³	0.002	THC < ARfD
200541745	CBD flavour oil	32	- ³	0.002	THC < ARfD
200541750	CBD flavour oil	32	- ³	0.001	THC < ARfD
190203186	Supplement with hemp extract	- ⁵	- ³	n.d.	-
190387556	CBD supplement	4	- ³	n.d.	-
190539777	CBD Lollipop	- ⁵	- ³	n.d.	-

¹ Average of 1–9 replicates measured with LC-MS/MS reported (for raw results see dataset²³, table sheet 2). Data reported for chromatographically separated CBD and Δ⁹-THC, not including their acids.

² No labelling about dosage provided on the label. For this reason, the consumption of the whole bottle at once was assumed as worst-case exposure scenario. Because the product was only labelled as “oil” and not as “food supplement”, this scenario is not deemed unrealistic, specifically since CBD is a novelty on the market and the product may be mistaken for a conventional edible oil²⁴.

³ Not analysed or outside calibration (most sample dilutions made for Δ⁹-THC analysis by far exceed the linear range for CBD, so that a separate dilution would have to be made to obtain a valid result, which was not possible in the context of the current study).

⁴ CBD liquid intended to refill electronic cigarettes. No national or international guideline for risk assessment of THC in liquids is available. For risk assessment, a LOAEL for inhalation of 2.8 mg/day was assumed²⁵, which was extrapolated to an ARfD of 1 µg/kg body weight using a safety factor of 30 and a bodyweight of 70 kg (also see rationale for oral ARfD in the text). An exposure of 10 ml liquid per day was assumed considering worst case exposure to vaping liquids ranging between 5–25 ml/day²⁶.

⁵ No labelling provided by manufacturer.

⁶ Values in brackets mean that the LOAEL is not directly exceeded based on the recommended daily dose according to labelling, but may be exceeded in realistic exposure scenarios. For example, Δ⁹-THC (mg/day) is calculated for food supplements on the basis of the recommended daily maximum dose or for 1 portion (if labelling of maximum recommended daily dose is missing). The LOAEL for these products may be exceeded with a probable intake of 2 portions/day. For tea products, a daily consumption of 8 g has been assumed if no other labelling was provided. However, much higher tea consumption is possible, so that a worst-case scenario has to be considered. For example, the very small portion size of 2.5 g labelled on the product with sample ID 190176314, would lead to a Δ⁹-THC intake of 0.5 mg per day. However, if only 5 times this amount is consumed, which is neither unexpected nor impossible considering typical herbal tea consumption, the LOAEL may be exceeded. For all products, a case-by-case judgement was conducted, also considering manufacturers' warning labels drawing attention to not exceeding the recommended daily intake. Also see Lachenmeier and Walch for further details on estimation of daily doses²⁴.

Abbreviations: CBD: cannabidiol; THC: Δ⁹-tetrahydrocannabinol; ARfD: acute reference dose of 1 µg THC per kg body weight²⁷; LOAEL: lowest observed adverse effect level of 2.5 mg Δ⁹-THC per day²⁷; LC-MS/MS: liquid chromatography/tandem mass spectrometry; n.d.: not detectable

ARC-18, 150 × 2.1 mm, 2.7 µm, Restek, Bad Homburg, Germany). The separation was a gradient starting with 20% eluent A (0.1 % formic acid in water) and 80% eluent B (0.1 % formic acid in methanol) for 18 min, followed by 5% A and 95% B for 5 min, and back to 20% A and 80% B for 7 min. All methods were validated and externally accredited according to ISO 17025 standard. Recently, the method reported satisfactory results for Δ⁹-THC during the international government chemist CBD food and cosmetic ring trial²⁸.

For toxicological evaluation of the results, the lowest observed adverse effect level (LOAEL) of 2.5 mg Δ⁹-THC per day published by the European food safety authority (EFSA) based on human data (central nervous system effects and pulse increase) was used²⁷. Taking safety factors (factor 3 for extrapolation from LOAEL to no observed adverse effect level (NOAEL) and factor 10 for interindividual differences, total factor 30) into account, an acute reference dose (ARfD) of 1 µg Δ⁹-THC per kg body weight was derived²⁷. In their assessment, the Panel on Contaminants in the Food Chain of EFSA also considered interaction between Δ⁹-THC and CBD, but found the information controversial and not consistently antagonistic²⁷. This is consistent with more recent research of Solowij *et al.*²⁹ that the effects of Δ⁹-THC may even be enhanced by low-dose CBD (e.g., as found in food supplements) and may be particularly prominent in infrequent cannabis users. However, the current scientific evidence does not allow for considering cumulative effects. The applicability of the acute reference dose (ARfD) of 1 µg Δ⁹-THC per kg body weight was re-confirmed by EFSA in 2020³⁰ and by the German Federal Institute for Risk Assessment (BfR) in 2021³¹. The BfR has also concluded that the previously suggested German guidance values, which had been considered in versions 1–3 of this article, no longer correspond to current scientific knowledge³¹. For this reason, the guidance values were removed from our assessment, which is now exclusively based on EFSA's suggestions. For further details on interpretation of results and toxicity assessment, see Lachenmeier *et al.*². A detailed rationale for the estimation of the daily dose of products to be applied for the risk assessment has been provided in a correspondence article²⁴.

Results and discussion

Direct pharmacological effect of CBD as explanation of adverse effects

There is not much evidence to assume that chemically pure CBD may exhibit Δ⁹-THC-like adverse effects. The World Health Organization (WHO) judged the compound as being well tolerated with a good safety profile³. Similar conclusions were made in a recent systematic review of CBD human trials³².

CBD doses in the food supplements on the market are typically much lower than the ones tested in clinical studies. Additionally, there is a 90-day experiment in rats with a hemp extract (consisting of 26% cannabinoids, out of which 96% were CBD and less than 1% Δ⁹-THC) from which a NOAEL of 100 mg/kg bw/day could be derived³³. Based on 100 mg/kg bw/day × 26% × 96%, this would be about

25 mg/kg bw/day for CBD (or 1750 mg/day for a person with a body weight of 70 kg). This NOAEL would not typically be reached by the CBD dosages in food supplements.

On the other hand, there are still many uncertainties and contradictions remaining regarding cannabinoid safety studies³⁴. The metabolism of CBD is very complex. The main human metabolite is 7-carboxy-cannabidiol (7-COOH-CBD; ~90 % of all drug-related substances measured in the plasma), which may form a reactive acyl-glucuronide^{35–37}. The toxicological profile of the metabolites has not been systematically investigated³⁴.

CBD conversion into THC as explanation of adverse effects

Some, partly older, *in vitro* studies put up hypotheses about the conversion of CBD to Δ⁹-THC under acidic conditions such as in artificial gastric juice^{21,38–40}. If these proposals could be confirmed with *in vivo* data, consumers taking CBD orally could be exposed to such high Δ⁹-THC levels that the threshold for pharmacological action could be exceeded⁴¹. However, taking a closer look at these *in vitro* studies raises some doubts. If CBD was to be converted to Δ⁹-THC *in vivo*, typical Δ⁹-THC metabolites should be detectable in blood and urine, but this has not been observed in oral or inhalatory CBD studies^{42–44}. Due to the contradicting results, a replication of the *in vitro* study of Merrick *et al.*²¹ was conducted using an extended experimental design. A more selective LC-MS/MS method and also an ultra-high pressure liquid chromatographic method with quadrupole time-of-flight mass spectrometry (UPLC-QTOF) were used to investigate the CBD degradation.

Under these conditions in contrast to Merrick *et al.*²¹, no conversion of CBD to Δ⁹-THC was observed in any of the samples. Only in case of the positive control (2 week storage in 0.5 mol/L HCl and 50% methanol), a complete degradation of CBD into 27% Δ⁹-THC and other not identified products (with fragments similar to the ones found in cannabidiol and Δ⁹-THC fragmentations but with other retention times) was observed (Table 1, underlying data²³). From an analytical viewpoint, the use of less selective and specific analytical methods, especially from the point of chromatographic separation, could result in a situation in which certain CBD degradation products might easily be confused with Δ⁹-THC due to structural similarities. Thus, similar fragmentation patterns and potentially overlapping peaks under certain chromatographic conditions might have led to false positive results in the previous studies. In conclusion of our degradation experiments, we agree with more recent literature^{45–47} that CBD would not likely react to Δ⁹-THC under *in vivo* conditions. The only detectable influence leading to degradation is strong acidity, which should be avoided in CBD formulations to ensure stability of products⁴⁸. Similar observations were recently provided by Yangsud *et al.* determining CBD as stable under stress conditions, other than acidic or alkaline conditions⁴⁹. Transformation of CBD may also occur in acidified plasma samples or during pyrolysis gas chromatography^{50,51}.

Δ^9 -THC contamination as cause of adverse effects

Out of 181 samples, 21 samples (12% of the collective) have the potential to exceed the Δ^9 -THC LOAEL and were assessed as harmful to health. 82 samples (45% of the collective) were classified as unsuitable for human consumption due to exceeding the ARfD (see Table 2, underlying data²³). Furthermore, all food samples (i.e., all samples except CBD liquids intended to refill electronic cigarettes) have been classified as non-compliant to Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods⁵² and therefore being unauthorized novel foods⁵³. The labelling of all food samples was also non-compliant to Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers⁵⁴, e.g. due to lack of mandatory food information such as ingredients list or use of unapproved health claims in accordance to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods⁵⁵. In summary, none of the food products in our survey was found as being fully compliant with European food regulations.

The Δ^9 -THC dose leading to intoxication is considered to be in the range of 10 to 20 mg (very high dose in heavy episodic cannabis users up to 60 mg) for cannabis smoking⁵⁶. The resorption of orally ingested Δ^9 -THC varies greatly inter-individually with respect to both total amount and resorption rate⁵⁷. This might be one of the reasons for the individually very different observed psychotropic effects. A single oral dose of 20 mg THC resulted in symptoms such as tachycardia, conjunctival irritation, “high sensation” or dysphoria in adults within one to four hours. In one out of five adults, a single dose of 5 mg already showed corresponding symptoms⁵⁸.

Some of the CBD oil supplements contained Δ^9 -THC in doses up to 30 mg (in this case in the whole bottle of 10 ml), which can easily explain the adverse effects observed by some consumers. Interestingly, it was observed that the symptoms reported with cannabidiol exposures in the so far largest epidemiological study²⁰ were Δ^9 -THC-like symptoms⁵⁹.

Most of the CBD oils with dosage of around 1 mg Δ^9 -THC per serving offer the possibility to achieve intoxicating and psychotropic effects due to this compound if the products are used off-label (i.e. increase of the labelled maximum recommended daily dose by factors of 3–5, which is probably not an unlikely scenario. Some manufacturers even suggest an increase of daily dosage over time). Generally, these products pose a risk to human health considering EFSA's ARfD that is considerably exceeded, even without consideration of THCA.

Hence our results provide compelling evidence that THC natively contained in CBD products may be a direct cause for adverse effects of these products. Obviously, there seems to be an involuntary or deliberate lack of quality control

of CBD products. Claims of “THC-free”, used by most manufacturers, even on highly contaminated products – sometimes based on the use of unsuitable analytical methodologies with limits of detection in the percentage range –, have to be treated as fraudulent or deceptive food information.

Conclusions

In light of the discussion about the three potential causative factors for adverse effects of CBD products, the described effects can be explained most probably by the presence of native THC as contaminant in the products rather than by direct action of CBD or its chemical transformation. The conclusions and findings of this study are further supported by the findings of Hazekamp⁶ reporting data from the Netherlands on cannabis oils according to which the labelling information for CBD and Δ^9 -THC was often different from the actual contents. In 26 out of 46 products the Δ^9 -THC content was >1 g/100 mL. Further corresponding results were reported in a study from the USA, in which the CBD content was correctly declared for only 26 of 84 CBD products and 18 of the products had Δ^9 -THC contents >0.317 g/100 g⁶⁰.

CBD degradation products are currently unknown and need to be characterized and toxicologically assessed, e.g. within the context of the novel food authorisation process. Until then, the safety of the products remains questionable. Furthermore, standardization and purification of the extracts need to be improved and stability of commercial products during shelf life should be checked (e.g. to prevent CBD degradation by avoiding acidity in ingredients etc.).

In our opinion the systematically high Δ^9 -THC content of CBD products is clearly a “scandal” on the food market. Obviously, the manufacturers have – deliberately or in complete ignorance of the legal situation – placed unsafe and unapproved products on the market and thus exposed the consumer to an actually avoidable health risk. In view of the growing market for such lifestyle food supplements, the effectiveness of the instrument of food business operators' own responsibility for food safety must obviously be challenged.

It has been claimed by C. Hillard that “many CBD products would be delivering enough THC along with it to provide a bit of a high and that's more likely where the relief is coming from”⁶¹. Our results have partially corroborated this opinion for a substantial number of products on the German market. Similarly, a recent survey reported that 22% out of 135 users of CBD products reported “feeling high” as common adverse effect¹². Nevertheless, the situation appears to have at least improved over time regarding extreme contents of THC: in 2020 only 4 samples were assessed as harmful to health, while in 2019 and 2018 this number was 10 and 7, respectively. A statistically significant decline of THC levels over all CBD products over the three years was not provable, however.

Currently we still observe a CBD market in the EU, where obviously considerable numbers of unsafe and misleadingly

labelled products are available. Due to consistent deficits in mandatory labelling including a lack of maximum recommended daily dose, dosages up to psychotropic levels (for THC) or pharmacological levels (for CBD) cannot be excluded with certainty. The risk also includes positive cannabis urine tests for several days, which may be expected from daily oral doses of more than 1 mg Δ^9 -THC^{1,2,62}. Therefore, about 15% of products in our study would probably lead to false-positive urine tests, which could have grave consequences for persons occupationally or otherwise required to prove absence of drug use or of doping in professional sports^{63–65}.

Obviously, the current regulatory framework is insufficient to adequately regulate products in the grey area between medicines and food supplements. For cannabis-derived products, such as CBD, the problem is aggravated by conflicting regulations in the narcotic, medicinal, and food law areas. For example, hemp extract-based products of similar composition were suggested to be treated as illegal narcotics, prescription-based medicinal products, or novel foods. Only recently, the EU commission clarified its position to not further consider cannabidiol as narcotic, but to advance the novel food approval procedure⁶⁶. Clearly for CBD products alongside other cannabis products, a regulated legalization (see e.g. Anderson *et al.*⁶⁷) would be preferable, introducing stricter regulations, such as mandatory labelling requirements, safety assessment, testing, pre-marketing approval and post-marketing surveillance (also see 43,68).

Data availability

Underlying data

Open Science Framework: Dataset for “Are adverse effects of cannabidiol (CBD) products caused by delta9-tetrahydrocannabinol (THC) contamination?” (Version 3) <https://doi.org/10.17605/OSF.IO/F7ZXY>²³

This project contains the following underlying data:

- Dataset for 'Are adverse effects of cannabidiol (CBD) products caused by delta9-tetrahydrocannabinol (THC) contamination' F1000 Research.xlsx (Version 3) (Excel spreadsheet with data underlying Table 1 and Table 2, missing data/empty cells correspond to values outside calibration (CBD) or not measured)

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

Acknowledgements

The authors would like to thank Sylvia Ullrich, Jutta Neumeister and Ingrid Kübel for their excellent technical support, sample preparation and measurements using LC-MS. Patricia Golombek is thanked for supervising the cannabinoid analyses since December 2020. Imke Gockel and Laura Riedel are thanked for their help in summarizing the raw data for samples analysed in 2020.

References

- Lachenmeier DW: **Hemp food products - ein problem?** *Deut Lebensm Rundsch.* 2004; **100**(12): 481–490.
[Publisher Full Text](#)
- Lachenmeier DW, Bock V, Deych A, *et al.*: **Hemp food products - ein update.** *Deut Lebensm Rundsch.* 2019; **115**(8): 351–372.
[Publisher Full Text](#)
- Expert Committee on Drug Dependence: **Cannabidiol (CBD) - Critical review report.** World Health Organization: Geneva, Switzerland. 2018.
[Reference Source](#)
- Sarill M: **Researching safety and efficacy of CBD, hemp extracts.** 2018; accessed on 2019-03-29.
[Reference Source](#)
- Büchi S: **Wirksamkeit von Cannabidiol: Klinische Studien mit Cannabidiol und Cannabidiol-haltigen Extrakten.** *Schweiz Z Ganzheitsmed.* 2017; **29**: 367–371.
[Publisher Full Text](#)
- Hazekamp A: **The trouble with CBD oil.** *Med Cannabis Cannabinoids.* 2018; **1**: 65–72.
[Publisher Full Text](#)
- Wilkinson J: **Cannabis, hemp and CBDs.** *Soft Drinks Int.* 2015; 42–44.
[Reference Source](#)
- Yin HY, Hadjokas N, Mirchia K, *et al.*: **Commercial cannabinoid oil-induced Stevens-Johnson syndrome.** *Case Rep Ophthalmol Med.* 2020; **2020**: 6760272.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bass J, Linz DR: **A case of toxicity from cannabidiol gummy ingestion.** *Cureus.* 2020; **12**(4): e7688.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Madera-Acosta A, Johnson-Wall H, Carbone LD, *et al.*: **Cannabidiol (CBD) oil toxicity mimicking extraglandular complications of Sjögren's syndrome.** *Rheumatol Adv Pract.* 2021; **5**(1): rkab010.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Laborde-Casterot H, Larabi IA, Dufayet L, *et al.*: **Does cannabidiol induce cannabinoid hyperemesis syndrome?** *Clin Toxicol (Phila).* 2020; **58**(12): 1351–1352.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Wheeler M, Merten JW, Gordon BT, *et al.*: **CBD (cannabidiol) product attitudes, knowledge, and use among young adults.** *Subst Use Misuse.* 2020; **55**(7): 1138–1145.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Press CA, Knupp KG, Chapman KE: **Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy.** *Epilepsy Behav.* 2015; **45**: 49–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Szaflarski JP, Bebin EM, Comi AM, *et al.*: **Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.** *Epilepsia.* 2018; **59**(8): 1540–1548.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Devinsky O, Marsh E, Friedman D, *et al.*: **Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.** *Lancet Neurol.* 2016; **15**(3): 270–278.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Herbst J, Musgrave G: **Respiratory depression following an accidental overdose of a CBD-labeled product: A pediatric case report.** *J Am Pharm Assoc (2003).* 2020; **60**(1): 248–252.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Chesney E, Oliver D, Green A, *et al.*: **Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials.** *Neuropsychopharmacol.* 2020; **45**(11): 1799–1806.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

18. Schmitz SM, Lopez HL, Marinotti O: **Post marketing safety of Plus CBD™ products, a full spectrum hemp extract: A 2-year experience.** *J Diet Suppl.* 2020; **17**(5): 587–598.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Choi NG, Marti CN, DiNitto DM, *et al.*: **Cannabis and synthetic cannabinoid poison control center cases among adults aged 50+, 2009-2019.** *Clin Toxicol (Phila).* 2021; **59**(4): 334–342.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Berger BA, Stolz U, Colvin J, *et al.*: **Epidemiology of cannabidiol related cases reported in the National Poison Data System – 2019-2020.** *Am J Emerg Med.* 2021; **48**: 218–223.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Merrick J, Lane B, Seabree T, *et al.*: **Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid.** *Cannabis Cannabinoid Res.* 2016; **1**(1): 102–112.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. PhEur Gastric juice, artificial (1039900): **European Pharmacopoeia.** 9th edition: *The European Directorate for the Quality of Medicines & HealthCare.* Strassbourg, France, 2019.
23. Lachenmeier DW: **Dataset for “Are adverse effects of cannabidiol (CBD) products caused by delta9-tetrahydrocannabinol (THC) contamination?”** (Version 3). 2021.
<http://www.doi.org/10.17605/OSF.IO/F7ZXV>
24. Lachenmeier DW, Walch SG: **Evidence for side effects of cannabidiol (CBD) products and their non-conformity on the European food market - response to the European Industrial Hemp Association [version 1; peer review: 2 approved].** *F1000Res.* 2020; **9**: 1051.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Skoczinski P, Carus M, Grotenhermen F, *et al.*: **Limit and guideline values for THC (tetrahydrocannabinol) in hemp foods.** European Industrial Hemp Association: Hürth, Germany.
[Reference Source](#)
26. National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice: **Toxicology of e-cigarette constituents.** In: *Public health consequences of e-cigarettes.* Washington (DC): National Academies Press (US); 2018.
[Reference Source](#)
27. EFSA Panel on Contaminants in the Food Chain (CONTAM): **Scientific opinion on the risks for human health related to the presence of tetrahydrocannabinol (THC) in milk and other food of animal origin.** *EFSA J.* 2015; **13**(6): 4141.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Hambidge T: **Government chemist CBD food and cosmetic ring trial final report. Cannabidiol and controlled cannabinoids.** UK National Measurement Laboratory for Chemical and Bio-Measurement. Teddington, UK.
[Reference Source](#)
29. Solowij N, Broyd S, Greenwood LM, *et al.*: **A randomised controlled trial of vapourised Δ⁹-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects.** *Eur Arch Psychiatry Clin Neurosci.* 2019; **269**(1): 17–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. EFSA (European Food Safety Authority), Arcella D, Cascio C, *et al.*: **Acute human exposure assessment to tetrahydrocannabinol (Δ⁹-THC).** *EFSA J.* 2020; **18**(1): e05953.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Bundesinstitut für Risikobewertung (BfR): **The BfR recommends acute reference dose as basis for assessing hemp-containing foodstuff: BfR Opinion No 006/2021 of 17 February 2021.** Bundesinstitut für Risikobewertung: Berlin, 2021; 2021.
[Publisher Full Text](#)
32. Larsen C, Shahinas J: **Dosage, efficacy and safety of cannabidiol administration in adults: a systematic review of human trials.** *J Clin Med Res.* 2020; **12**(3): 129–141.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Marx TK, Reddeman R, Clewell AE, *et al.*: **An assessment of the genotoxicity and subchronic toxicity of a supercritical fluid extract of the aerial parts of hemp.** *J Toxicol.* 2018; **2018**: 8143582.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Cerne K, Pezdir T: **Peer Review Report For: Evidence for side effects of cannabidiol (CBD) products and their non-conformity on the European food market - response to the European Industrial Hemp Association [version 1; peer review: 2 approved].** *F1000Res.* 2020; **9**: 1051.
[Publisher Full Text](#)
35. Ujváry I, Hanuš L: **Human metabolites of cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy.** *Cannabis Cannabinoid Res.* 2016; **1**(1): 90–101.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Harvey DJ, Samara E, Mechoulam R: **Comparative metabolism of cannabidiol in dog, rat and man.** *Pharmacol Biochem Behav.* 1991; **40**(3): 523–532.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Regan SL, Maggs JL, Hammond TG, *et al.*: **Acyl glucuronides: the good, the bad and the ugly.** *Biopharm Drug Dispos.* 2010; **31**(7): 367–95.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Adams R, Pease DC, Cain CK, *et al.*: **Structure of cannabidiol. VI. Isomerization of cannabidiol to tetrahydrocannabinol, a physiologically active product. Conversion of cannabidiol to cannabinol.** *J Am Chem Soc.* 1940; **62**(9): 2402–2405.
[Publisher Full Text](#)
39. Adams R, Cain CK, McPhee WD, *et al.*: **Structure of cannabidiol. XII. Isomerization to tetrahydrocannabinols.** *J Am Chem Soc.* 1941; **63**(8): 2209–2213.
[Publisher Full Text](#)
40. Watanabe K, Itokawa Y, Yamaori S, *et al.*: **Conversion of cannabidiol to Δ⁹-tetrahydrocannabinol and related cannabinoids in artificial gastric juice, and their pharmacological effects in mice.** *Forensic Toxicol.* 2007; **25**(1): 16–21.
[Publisher Full Text](#)
41. Lachenmeier DW, Walch SG: **Current status of THC in German hemp food products.** *J Ind Hemp.* 2006; **10**(2): 5–17.
[Publisher Full Text](#)
42. Lachenmeier DW, Walch SG: **Analysis and toxicological evaluation of cannabinoids in hemp food products - a review.** *Electron J Environ Agric Food Chem.* 2005; **4**: 812–826.
[Publisher Full Text](#)
43. Manthey J: **Cannabis use in Europe: Current trends and public health concerns.** *Int J Drug Policy.* 2019; **68**: 93–96.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Kintz P: **Vaping pure cannabidiol e-cigarettes does not produce detectable amount of Δ⁹-THC in human blood.** *J Anal Toxicol.* 2021; **44**(9): e1–e2.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Nahler G, Grotenhermen F, Zuardi AW, *et al.*: **A conversion of oral cannabidiol to delta9-tetrahydrocannabinol seems not to occur in humans.** *Cannabis Cannabinoid Res.* 2017; **2**(1): 81–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Grotenhermen F, Russo E, Zuardi AW: **Even high doses of oral cannabidiol do not cause THC-like effects in humans: Comment on Merrick *et al.* Cannabis and Cannabinoid Research 2016; 1(1): 102–112; DOI: 10.1089/can.2015.0004.** *Cannabis Cannabinoid Res.* 2017; **2**(1): 1–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Ma H, Li H, Liu C, *et al.*: **Evaluation of cannabidiol's inhibitory effect on alpha-glucosidase and its stability in simulated gastric and intestinal fluids.** *J Cannabis Res.* 2021; **3**(1): 20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Golombek P, Müller M, Barthlott I, *et al.*: **Conversion of Cannabidiol (CBD) into Psychotropic Cannabinoids Including Tetrahydrocannabinol (THC): A Controversy in the Scientific Literature.** *Toxics.* 2020; **8**(2): 41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
49. Yangsud J, Santasanasuwan S, Ahkharachinoreh P, *et al.*: **Stability of cannabidiol, Δ⁹-tetrahydrocannabinol, and cannabinol under stress conditions.** *Adv Trad Med.* 2021; in press.
[Publisher Full Text](#)
50. Dybowski MP, Dawidowicz AL, Typek R, *et al.*: **Conversion of cannabidiol (CBD) into Δ⁹-tetrahydrocannabinol (Δ⁹-THC) during protein precipitations prior to plasma samples analysis by chromatography – Troubles with reliable CBD quantitation when acidic precipitation agents are applied.** *Talanta.* 2020; **220**: 121390.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Czégény Z, Nagy G, Babinszki B, *et al.*: **CBD, a precursor of THC in e-cigarettes.** *Sci Rep.* 2021; **11**(1): 8951.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. European Parliament and the Council of the European Union: **Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the Council and Commission Regulation (EC) No 1852/2001.** *Off J Europ Union.* 2015; **L327**: 1–22.
[Reference Source](#)
53. Lachenmeier DW, Rajcic de Rezende T, *et al.*: **Recent jurisdiction confirms novel food status of hemp extracts and cannabidiol in foods – Classification of cannabis foods under narcotic law is still ambiguous.** *Deut Lebensm Rundsch.* 2020; **116**: 111–119.
[Publisher Full Text](#)
54. European Parliament and the Council of the European Union: **Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and Commission Regulation (EC) No 608/2004.** *Off J Europ Union.* 2011; **L304**: 63.
[Reference Source](#)
55. European Parliament and the Council of the European Union: **Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods.** *Off J Europ Union.* 2006; **L404**: 9–25.
[Reference Source](#)

56. Lachenmeier DW, Rehm J: **Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach.** *Sci Rep.* 2015; **5**: 8126.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. Grotenhermen F: **Pharmacokinetics and pharmacodynamics of cannabinoids.** *Clin Pharmacokinet.* 2003; **42**(4): 327–360.
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Meier H, Vonesch HJ: **[Cannabis poisoning after eating salad].** *Schweiz Med Wochenschr.* 1997; **127**(6): 214–218.
[PubMed Abstract](#)
59. Vodovar D, Caré W, Dufayet L, et al.: **Cannabidiol-induced toxicity: who is the culprit?** *Am J Emerg Med.* 2021; S0735-6757(21)00485-X. in press.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Bonn-Miller MO, Loflin MJE, Thomas BF, et al.: **Labeling accuracy of cannabidiol extracts sold online.** *JAMA.* 2017; **318**(17): 1708–1709.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Freedman DH: **High on the hype.** *Newsweek.* 2019; 30–41.
[Reference Source](#)
62. Habel S, Sproll C, Teipel J, et al.: **Positive Cannabis-Urintests durch kommerzielle Cannabidiol-Produkte.** *Toxichem Krimtech.* 2020; **87**(1): 10–8.
[Publisher Full Text](#)
63. Lachenmeier DW, Diel P: **A warning against the negligent use of cannabidiol in professional and amateur athletes.** *Sports (Basel).* 2019; **7**(12): 251.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Connors N, Kosnett MJ, Kulig K, et al.: **ACMT position statement: Interpretation of urine for tetrahydrocannabinol metabolites.** *J Med Toxicol.* 2020; **16**(2): 240–242.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Mareck U, Füssli G, Geyer H, et al.: **Preliminary data on the potential for unintentional antidoping rule violations by permitted cannabidiol (CBD) use.** *Drug Test Anal.* 2021; **13**(3): 539–549.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. European Commission: **Cannabidiol-Produkte können als Lebensmittel eingestuft werden.** (in German) [Cannabidiol products can be classified as food products]. 2020.
[Reference Source](#)
67. Anderson P, Berridge V, Conrod P, et al.: **Reframing the science and policy of nicotine, illegal drugs and alcohol – conclusions of the ALICE RAP Project [version 1; peer review: 2 approved].** *F1000 Res.* 2017; **6**: 289.
[PubMed Abstract](#) | [Publisher Full Text](#)
68. Lachenmeier DW, Walch SG: **Cannabidiol (CBD): a strong plea for mandatory pre-marketing approval of food supplements.** *J Consum Prot Food Saf.* 2020; **15**: 97–98.
[Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 3

Reviewer Report 24 August 2020

<https://doi.org/10.5256/f1000research.28743.r69794>

© 2020 Hazekamp A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Arno Hazekamp

Hazekamp Herbal Consulting BV, Leiden, The Netherlands

Great job done by the authors. This manuscript is ready for indexing.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: medicinal cannabis cultivation, quality control, development of administration forms, clinical trials, patient surveys.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 2

Reviewer Report 06 July 2020

<https://doi.org/10.5256/f1000research.24583.r59941>

© 2020 Auwärter V. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Volker Auwärter

Institute of Forensic Medicine, Forensic Toxicology, Medical Center - University of Freiburg, Freiburg, Germany

With respect to the two previous reviews I will refrain from summarizing the article once more.

Although the article addresses an important issue and the hypothesis of THC residues being responsible for some of the adverse effects of CBD preparations is plausible and supported by the data, I miss the discussion of two relevant points:

1. No details are given regarding the extraction of the products. Was the 'total THC content' measured by heat-induced decarboxylation of THC acid A? That would be close to the procedure used by most forensic laboratories in Germany. The author's response to reviewer 2 (page 4, comments #3 and #8) suggests, however, that THC acid A was determined separately. If the 'total THC content' was given as the sum of THC and THC acid A after correction for the molecular weight the dose would be overestimated (maximum conversion rates of smoked, 'vaped' or baked cannabis were usually reported to be below 70%). The available THC doses after oral ingestion without heating the material would be even lower (depending on the THC acid A content).
2. Regarding the THC dose required to produce psychotropic effects the authors did not discuss the 'inverse agonist' like properties of CBD at the CB1 receptor (McPartland *et al.*, 2015¹) which have been shown to reduce the intoxicating effects of THC (e.g. Solowij *et al.*, 2019²). This might affect the LOAEL and the ARfD of THC when contained in CBD rich products as these values were not yet assessed for such cannabinoid preparations.

Page 8: The German guidance value seems to be several orders of magnitude (up to 4) lower than the CBD contents in the products.

References

1. McPartland JM, Duncan M, Di Marzo V, Pertwee RG: Are cannabidiol and $\Delta(9)$ -tetrahydrocannabinol negative modulators of the endocannabinoid system? A systematic review. *Br J Pharmacol.* 2015; **172** (3): 737-53 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Solowij N, Broyd S, Greenwood LM, van Hell H, et al.: A randomised controlled trial of vaporised $\Delta 9$ -tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. *Eur Arch Psychiatry Clin Neurosci.* 2019; **269** (1): 17-35 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Not applicable

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Forensic Toxicology, Metabolism, NPS, Cannabinoids

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 09 Jul 2020

Dirk W. Lachenmeier, Chemisches und Veterinäruntersuchungsamt (CVUA) Karlsruhe, Karlsruhe, Germany

Thank you for your comments!

1. Regarding the extraction and measurement of the products, no heat was applied during the whole procedure. The samples were extracted and/or diluted using solvents at room temperature and then subjected to LC-MS/MS as described in the methods section. By this method, tetrahydrocannabinolic acid (THCA) can be distinguished from both Δ^9 -THC and Δ^8 -THC (the methods section in version 1 of the paper is more detailed in this regard). As THCA is not psychotropic, we believe that the use of "total THC content", which has been historically based on gas chromatographic determination always leading to decarboxylation in the injection port, is not informative for meaningful risk assessment of cannabis products (for details on risk assessment see¹). Hence, we only report the specific content of Δ^9 -THC in Table 2 of our article (in our article THC is used as abbreviation for Δ^9 -tetrahydrocannabinol but not for "total THC", see introduction line 2). The many samples that exceed the German guideline value (which – as footnote 6 in table 2 correctly states – indeed refers to total THC), exceed it already for Δ^9 -THC alone. Therefore, we have disregarded THCA for this assessment and refrained from calculating sums of THC and THCA. This means that the assumption of the reviewer that we might have overestimated the risk by including THCA is unfounded. Considering the German guideline values, our approach purely based on Δ^9 -THC is even for the benefit of the manufacturer, as we believe it is over-conservative to include precursors of Δ^9 -THC formation in risk assessment of products for which there is not typically a hazard of decarboxylation (e.g., when the foods are intended for baking). It should be also considered that the more recent EFSA ARfD value is also based on Δ^9 -THC and not on total THC.
2. The reviewer is correct that risk assessment methods of mixtures are currently evolving and have not been applied to mixtures of cannabinoids. Typically, to provide such a risk assessment would be the responsibility of the food business operator and not the responsibility of the authority. Hopefully, such a risk assessment will be provided during the toxicological assessments necessary during the novel food application procedure, which several companies have initiated. In light of the currently available evidence, we do not believe a change in our risk assessment based on EFSA ARfD would be justified. For example, Solowij et al.² state that the effects of THC may even be enhanced by low-dose CBD (most food supplements would fall in the low CBD dose range) and may be particularly prominent in infrequent cannabis

users. Furthermore, Haney et al.³ found that oral CBD does not reduce the reinforcing, physiological, or positive subjective effects of smoked cannabis. Niemsink and van Laar⁴ acknowledge that CBD may counteract the negative effects of THC, but warned that the question remains how laboratory results translate to the real world. Furthermore, a recent survey reported a high prevalence of side effects in 74 out of 135 young adult cannabidiol users (55%), with dry mouth, feeling high, change in appetite and fatigue most commonly reported.⁵ All in all, we strongly believe that the current evidence does not allow to negate side effects of THC in commercial cannabidiol products despite the potential antagonistic effect of CBD.

3. We agree with the reviewer that the German guidance value is typically one to several orders of magnitude lower than the THC contents in the products (please note that the guideline value is for THC. There is currently no guideline value for CBD available).

References:

1. Lachenmeier DW, Bock V, Deych A, et al.: Hemp food products - an update. *Deut Lebensm Rundsch.* 2019; **115**: 351–372. [Publisher Full Text](#)
2. Solowij N, Broyd S, Greenwood LM, van Hell H, et al.: A randomised controlled trial of vaporised Δ^9 -tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. *Eur Arch Psychiatry Clin Neurosci.* 2019; **269** (1): 17-35 [PubMed Abstract](#) | [Publisher Full Text](#)
3. Haney, M., Malcolm, R., Babalonis, S. et al. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis. *Neuropsychopharmacol* **41**, 1974–1982 (2016). <https://doi.org/10.1038/npp.2015.367>
4. Niesink RJM and van Laar MW (2013) Does cannabidiol protect against adverse psychological effects of THC? *Front. Psychiatry* 4:130. <https://doi.org/10.3389/fpsyt.2013.00130>
5. Meghann Wheeler, Julie Williams Merten, Benjamin T Gordon & Hanadi Hamadi (2020) CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults, *Substance Use & Misuse*, 55:7, 1138-1145, <https://doi.org/10.1080/10826084.2020.1729201>

Competing Interests: none

Reviewer Report 17 February 2020

<https://doi.org/10.5256/f1000research.24583.r59880>

© 2020 Hazekamp A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Arno Hazekamp

Hazekamp Herbal Consulting BV, Leiden, The Netherlands

The authors of this manuscript have addressed my questions and concerns in a satisfactory manner. I see no more objection for indexing of this very welcome manuscript.

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: medicinal cannabis cultivation, quality control, development of administration forms, clinical trials, patient surveys.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 17 September 2019

<https://doi.org/10.5256/f1000research.21875.r53494>

© 2019 Parker L. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linda A. Parker

Department of Psychology, Neuroscience Graduate Program, University of Guelph, Guelph, ON, Canada

Commercial CBD products are usually crude extracts from whole hemp plant material, that are available for purchase in several venues. These extracts have been reported to contain cannabinoid mixtures rather than pure CBD, and are then mixed into edible oils to obtain CBD oil. They are marketed as being free of psychoactive component, i.e. THC. Anecdotal reports of THC-

like side effects from these mixtures have been reported. Three hypotheses for these side effects are posed: i) direct pharmacological effect of CBD-for which there is little evidence, ii) the degradation of CBD to THC due to acidic hydrolysis in the stomach following oral consumption, and iii) THC directly contained in the products as a by-product due to co-extraction and enrichment or contamination. The article investigated the latter two of these hypotheses.

CBD degradation: Differently concentrated CBD in methanolic solutions was evaluated in a range corresponding to typical amounts consumed in supplements based on commercial CBD supplied by Merck. These solutions were exposed to an artificial gastric juice at different incubation times and under different environmental conditions. In no case was there any conversion of CBD to THC in any of the samples. Indeed, if CBD is converted to THC in the stomach, among consumers taking CBD it would be expected that THC metabolites would be detectable in the blood and urine, but this has not been shown in oral CBD studies.

THC contamination as a cause of side effects: A sampling of all available CBD products registered as food supplement in the German State Baden-Württemberg, other hemp extract products in retail, as well as products available at the warehouse of a large internet retailer were evaluated for THC content between December 2018 and July 2019. Of the 28 samples described in Table 2, none of the products was compliant with European food regulations and most of the samples contained THC, some at a dose that would be expected to lead to intoxication. Therefore, the results provided evidence that THC contamination in the CBD products is the most likely cause for the anecdotal THC-like side effects reported. Although it would have been even more informative to have a clear indication of the CBD content of each of the samples, the data clearly present evidence that the products are mislabeled and that THC-like side effects reported by patients is likely the result of contamination of the product with THC, which was the purpose of the study.

This is an important manuscript that will clear up the misconception that CBD is converted to THC in gastric juices of users.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Cannabinoids, nausea, CBD, rat models, addiction, learning

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 31 Jan 2020

Dirk W. Lachenmeier, Chemisches und Veterinäruntersuchungsamt (CVUA) Karlsruhe, Karlsruhe, Germany

Thank you for your assessment of our article.

Competing Interests: none

Reviewer Report 19 August 2019

<https://doi.org/10.5256/f1000research.21875.r52382>

© 2019 Hazekamp A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Arno Hazekamp

Hazekamp Herbal Consulting BV, Leiden, The Netherlands

The manuscript focuses on the quality of CBD oils, which is a meaningful and contemporary issue. Table 2 is the core of the study, because it compares the **claimed** composition of CBD oil, with **lab results** obtained by the authors. The conclusion is that the currently available products in Germany are often not what they claim to be.

Unfortunately, the authors did not analyze the actual CBD content of many of the products, and they assume that their own lab analyses are fully accurate, without proving or showing why. The authors use two different methods of analysis without explaining why one method is not sufficient. Also, in many parts of the text, they explain the current situation concerning CBD product without realizing that many readers may not have enough background information to follow their line of reasoning. The manuscript should be rewritten to explain basic concepts better.

Also, more data should be added to table 2, particularly about CBD content of the products analyzed. Right now, CBD analysis data is missing for more than half of the samples. It is not clear why so many of the products have not been studied for CBD content, and this undermines the strength of the paper. In general, the idea behind the study is very good, but the execution is relatively poor because it only focuses on the THC content of the product analyzed.

Please see my annotated copy of the article [here](#) for additional comments.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: medicinal cannabis cultivation, quality control, development of administration forms, clinical trials, patient surveys.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 31 Jan 2020

Dirk W. Lachenmeier, Chemisches und Veterinäruntersuchungsamt (CVUA) Karlsruhe, Karlsruhe, Germany

Thank you for your detailed comments and annotations in the copy. As requested, we have revised the background information to clarify the basic concepts.

Regarding the criticism of lack of CBD analysis, it must be remarked that the aim of our paper was to investigate the side effects of the products due to THC contamination. Hence, the main purpose of our analytical efforts was to accurately determine the content of THC for health risk assessment. See also the title of the paper, which is regarding THC and not CBD. The analysis of CBD is more or less a secondary addition to the aim of our study, which was THC analysis. It is therefore true that CBD quantification is missing for many samples for the pure reason that CBD and THC contents are so different and CBD was outside the linearity of our calibration. For cost reasons, we have refrained from determining CBD using a second method or dilution (it is of note that we had not specific funding for this study and have to generally work economically as tax-payer funded institute). In the legal evaluation of the products, the CBD content is more or less unimportant as long as the content is

below the level of pharmacological action (for food products). As all products had to be objected for various reasons (lack of novel food authorisation, THC contents outside of acceptable levels, mandatory labelling etc.), the CBD quantification was not relevant as well because the issue of consumer deception by mislabelling of CBD is secondary to the safety aspects posed by THC or the use of non-approved, potentially unsafe novel food ingredients.

Regarding the question on analytical methods, we actually have confidence in our analytical methods and they are fully validated and our institute is externally accredited according to ISO 17025. Nevertheless, as there is no official method for CBD analysis available, we have confirmed our results with a second procedure to even further improve confidence and validity. As of now, we believe that both methods perform similarly and could both be used in instances of laboratories without access to two different instruments.

To improve the strength of the paper, as requested by the reviewer, we have added the results of 39 samples measured in the meantime (new total 67 samples). In many of these samples it was also possible to quantify CBD. The measurement of these additional samples corroborates our previous results and interpretation, and we hope that the sample collective now appears as sufficient for publication.

Regarding the comments in the annotated copy, we have revised the text considering all suggested changes, except for the following comments for which we provide a detailed response (comment numbering according to Adobe Acrobat comment numbering in annotated copy of reviewer):

- Page 3, comment #2 "Not yet. The European Food Safety Authority (EFSA) has advised that CBD should be classified as a novel food. But now it is up to individual EU member states to implement that advise into national legislation. Some countries may decide to not follow the advise."

We disagree with this comment. The classification of CBD and hemp extracts (which was published in the novel food catalogue of the European commission and not by EFSA, see: https://ec.europa.eu/food/safety/novel_food/catalogue/search/public/index.cfm?ascii=Cannabinoids) is a consensus decision of all EU member states. EU regulations such as the novel food regulation are binding in its entirety and directly applicable in all Member States. Therefore there appears to be no leverage for member states to act in infringement of the novel food regulation. If you check the Rapid Alert System for Food and Feed (RASFF) portal for CBD (<https://webgate.ec.europa.eu/rasff-window/portal/?event=SearchByKeyword&NewSearch=1&Keywords=cbd>), there are more than 80 notifications of CBD products as „unauthorised novel food ingredient“ from various countries including Spain, Belgium, Denmark, Germany, Austria, Switzerland, Slovenia, Lithuania, Italy, Sweden. In Germany, there are currently at least 7 court rulings that confirmed the status of CBD as novel food and confirmed the actions of the authorities (typically removal of products from the market).

For details on novel food status and German court rulings, please refer to: Lachenmeier DW, Rajcic de Rezende T, Habel S, et al.: Recent jurisdiction confirms novel food status of hemp extracts and cannabidiol in foods – Classification of cannabis foods under narcotic law is still ambiguous. Deut Lebensm Rundsch. 2020;116: 111-119. DOI:

<https://doi.org/10.5281/zenodo.3631608>

The following court rulings confirmed the novel food status of cannabidiol and hemp extracts:

VG Cottbus 08.01.2020 Az. 3 L 230/19

OVG Lüneburg 12.12.2019 Az. 13 ME 320/19

VG Hannover 18.11.2019 Az. 15 B 3035/19

VG Gießen 11.11.2019 Az. 4 L 3254/19.GI

VGH Baden-Württemberg 16.10.2019 Az. 9 S 535/19

VG Düsseldorf 27.09.2019 Az. 16 L 2333/19

VG Stade 05.09.2019 Az. 6 B 735/19

- Page 5, comment #5: "Based on your table, this product seems to be the most reliable. But in fact this sample may not contain any cannabinoids at all."

Some cannabinoids could be qualitatively detected in this sample around the detection limit of the method.

- Page 4, comment #1: "It is not common to use two methods and use the average. Does that mean you do not trust your own methods?"

In our line of work in providing expert opinions that may be used in court cases, it is often common to use two methods, especially in cases where a reference procedure is not established or when there may be grave consequences in application of the results, such as taking products from the market. We currently cannot see the reason why doing more than perhaps absolutely necessary might hinder publication of such results.

Furthermore, as there was a discrepancy between our results and some previous studies regarding *in vitro* formation of THC from CBD, we found it prudent to confirm our results using a second methodology.

- Page 4, comments #3 and #8 regarding THCA, CBDA and CBN

Basically, we can accurately quantify all these other cannabinoids using the same method. However, as the results of these are not presented and unnecessary for the current paper, we have deleted all mentions of these compounds in the method section to avoid confusion.

- Page 5, comment #7: "Why are some samples measured 1 time, and others up to 6 times?"

The number of replicates depended on several factors, sometimes restricted by the very low sample volume we have received. Typically in the cases with highest THC content leading to a judgment of "non-safe food product" we aimed for at least 3 if possible 5 replicates. In certain cases, more replicates were made, for example when several dilutions were within the linearity range.

Competing Interests: none

Comments on this article

Version 2

Author Response 09 Jul 2020

Dirk W. Lachenmeier, Chemisches und Veterinäruntersuchungsamt (CVUA) Karlsruhe, Karlsruhe, Germany

Thank you for the comment. We did not observe Δ^8 -THC in our degradation experiments (please note that Δ^8 -THC was included in the spectrum of our analytes, see methods sections of article version 1). Otherwise, the conversion of CBD to Δ^8 -THC was reported under certain acidic conditions. See our recent review on conversion of cannabidiol¹.

References

1. Golombek P, Müller M, Barthlott I, Sproll C, Lachenmeier DW. Conversion of Cannabidiol (CBD) into Psychotropic Cannabinoids Including Tetrahydrocannabinol (THC): A Controversy in the Scientific Literature. *Toxics*. 2020; 8(2):41. <https://doi.org/10.3390/toxics8020041>

Competing Interests: none

Reader Comment 24 Jun 2020

Istvan Ujvary, iKem BT, Hungary

I could have missed it but did not find data on the delta-8-THC content. This THC isomer, which is thermodynamically more stable than the delta-9 isomer thus its formation from CBD is plausible under acidic conditions, is also 'psychotropic' so may contribute to the overall psychoactivity of such hemp preparations.

Competing Interests: none

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research